Topic Listing for Merck

Abr Accelerated Filer Non-accelerated
Accounting Firm Accounting Share-based Compensation
Accumulated Funding Deficiency Acquisitions
Act Additional Information
Additional Lawsuits Additional Payments Benefits
Adjusted Libo Rate Adjustment Amount
Adjustments Administration
Administrative Agent Administrative Questionnaire
Admission Ticket Adopt Simple Majority Vote
Adoption Change-in-control Program Affiliate
Affiliate Guarantee After Merger Completed New Merck Increasingly Dependent Sophisticated
Aggregate Amount Maturities Agreement
Alternate Base Rate Amended 1999
Amended 2002 Amended Credit Agreement
Amended Restated 2006 Amendment
Amendment Termination Amendments
Amendments Articles Incorporation Bylaws Change Amendments Supplements Because They Contain Important Information
Analysis Liquidity Capital Resources Animal Health Business
Animal Health Disposition Animal Health Field
Animal Health Subsidiaries Animal-based Test Methods
Annual Benefits Payable Merck Inc Retirement Plans Antitrust Law
Appeal Denied Claim Appendix
Applicable Commitment Fee Rate Applicable Facility Fee Rate
Applicable Lending Office Applicable Percentage
Application Approved 2002
Approved Fund Arbitration Proceeding Commenced Centocor Against Schering-plough Result Combined
Asset Sale Facility Assignee
Assignment Assumption Astrazeneca
Atherosclerosis Audit Committee Charter
Audit Committees Report Audit Fees
Audit-related Fees Ause They Contain Important Information
Automatic Distribution Availability Date
Availability Period Awp Litigation Investigations
Background Balance Sheet
Base Salary Basic Redesignation Rules
Basis Presentation Bba Libor
Because Market Price Merck Common Shares Fluctuate Schering-plough Before Vote
Behind Merger Peter Kellogg Beneficial Ownership Reporting Compliance
Beneficiary Designations Benefits
Biologics Carry Unique Risks Uncertainties Negative Impact Future Board
Board Chair Ceo Board Committee Meetings
Board Directors Statement Opposition Proposal Board Directors Statement Opposition Resolution
Boards Role Strategic Planning Bone Respiratory Immunology Dermatology
Bonus Awards Borrower
Borrowing Borrowing Request
Borrowings Credit Facilities Bridge Loan Facility
Building New Culture Business
Business Products Buyer Animal Health Executive
By-laws Calculation Estimated Consideration Transferred
Call Option Agreement Cancer
Cancer Ctcl Capital Expenditures
Capital Lease Obligations Capital Stock
Capitalization Cardiovascular
Cash Award Methodology Cash Dividends Paid Per Common Share
Cash Equivalents Categorical Independence Standards
Cautionary Factors Affect Future Results Cautionary Statements Private Securities Litigation Reform Act 1995
Ceo Ceo-objectives Performance
Certain Related Person Transactions Certain Schering-ploughs Mercks Major Products Going Lose Patent
Certification Chairman President Ceo Merck Inc
Change Control Change Control Payment Benefit Estimates
Change Law Change Tax Law
Change-in-control Arrangements Changes Laws Regulations Adversely Affect Business New Merck
Cholesterol Franchise Cinv
Click Here Image Above View Video Transcripts 8220behind Click Here View Video Transcripts Behind Merger Mirian
Closing Closing Accounts
Closing Date Closing Financial Documents
Code Combined Fail Realize Anticipated Cost Savings Revenue Enhancements
Commercial Litigation Commitment
Common Stock Common Stock Market Prices
Communication Includes 8220 Forward-looking Statements8221 Within Meaning Safe Comparison Five-year Cumulative Total Return
Compensation Analyses Reviews Compensation Benefits Committee Report
Compensation Chief Executive Officer Compensation Chief Executive Officers
Compensation Clark Kellogg Canan Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Discussion Analysis Compensation Program Objectives Rewards
Compensation Program Objectives Strategy Competition
Competition Health Care Environment Competition Laws
Competition Parties Make Difficult Schering-plough Acquire License New Compliance
Concentrations Credit Risk Segment Information Confidentiality Agreement
Connection Proposed Transaction Schering-plough Registration Statement Including Joint Consent Independent Registered Public Accounting Firm
Consolidated Statement Comprehensive Income Consolidated Statement Income
Consolidated Statement Retained Earnings Constraint Corporate Action
Contain Important Information Contingencies Environmental Liabilities
Contract Contractual Obligation
Contribution Contribution Agreement
Contribution Reference Date Contribution Value
Control Conversion Common Stock Accounts
Cordaptive Corporate Governance
Costs Associated Exit Disposal Activities Costs Expenses Equity Income
Credit Agreement Credit Facilities
Credit Group Credit Party
Critical Accounting Policies Estimates Date
Death Decision Order
Deductions Distributions Default
Default Designation Defaulting Lender
Deferral Program Deferral Program Investment Alternatives
Deferred Stock Units Definitions
Definitive Additional Materials Delay Completing Merger Beyond 2009 Reduce Eliminate Benefits
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Depreciation Property Equipment Derivatives Trading
Description Business Description Mercks Business
Designated Equity Issuances Designated Financings
Designated Incurrence Designing New Merck Organization
Determination Claim Developments Following Regulatory Approval Adversely Affect Sales Mercks
Developments Following Regulatory Approval Adversely Affect Sales Schering-ploughs Diabetes
Diabetes Obesity Director Compensation
Director Officer Liability Directors
Directors Whose Terms Expire 2006 Disclosure Notice
Discontinuance Amendment Plan Discussion Cash Flow
Dispose Disqualified Stock
Distribution Commences Distribution Deferred Compensation Accounts
Distribution Schedule Distributions
Dividends Documents Incorporated Reference
Domestic Lending Office Domestic Relations Orders
Domestic Restricted Investment Duration Amendment Plan Termination
Duties Responsibilities Earnings Conference Call
Earnings Per Common Share Ecause They Contain Important Information
Edit Agreement Effect Change Control
Effect Sections 280g 4999 Code Effective Date
Effects Other Benefit Plans Eip Awards
Election Directors Election Investment Alternatives
Electronic Submission Elia Olbert
Eligibility Eligible Assignee
Emend Ement Joint Proxy Statement Including Amendments Supplements Because
Employee Employees
Employment Contracts Encumbrance
End Potential Frustration Shareholder Majority Enhance Study Litigation Update
Enterprise Value Entities Mac
Entities Plan Entry Material Definitive Agreement
Ents Supplements Because They Contain Important Information Environmental
Environmental Laws Environmental Liability
Environmental Matters Equity Compensation Plan Information
Equity Income Equity Income Affiliates
Equity Income Affiliates Dollars Equity Interests
Equity Issuance Equity Issuance Treasury Shares
Equity Method Accounting Equity Securities
Equity-based Assumptions Erisa
Erisa 503 Erisa Affiliate
Erisa Litigation Establishment Purpose
Estimated Future Benefit Payments Estimates
Eurocurrency Liabilities Eurodollar
Eurodollar Lending Office Event
Evp President Merck Manufacturing Division Evp President Merck Research Laboratories
Evp President Schering Plough Research Institute Exact Name Registrant Specified Charter
Excluded Taxes Executive Overview
Exercise Right Vote Existing Credit Agreement
Existing Products License Agreement Expert
Explanatory Face Pricing Pressure Respect Products
Failure Complete Merger Negatively Impact Stock Price Future Fair Market Value Merck Common Stock
Fair Value Financial Instruments Fair Value Measurements
Federal Funds Effective Rate Federal Income Tax Consequences
Federal Securities Litigation Fee Letter
Fees Services Provided Independent Registered Public Accounting Firm Final Adjustment Amount
Financial Guidance Financial Highlights
Financial Information Financial Instruments Market Risk Disclosures
Financial Instruments Not Measured Fair Value Financial Officer
Financial Statements Financial Statements Exhibits
Financing Activities Five-year Credit Agreement
Focus People Foreign Currency Risk Management
Foreign Currency Translation Foreign Securitization Facility
Foreign Subsidiary Form 10-k
Form 10-q Form Guarantee Joinder Agreement
Form Pricing Term Sheet Former Name Address Changed Since Last Report
Forward Looking Statement Forward Looking Statements
Forward-looking Statement Forward-looking Statements
Fosamax Litigation Update French Matter
Frequency Timing Full-year 2009 Financial Results
Fy-end Option Sar Values Gaap
General Assumptions General Provisions
Geographic Area Information Global Hiv Aids-tb-malaria Pandemics
Global Restructuring Efforts Global Restructuring Program
Goodwill Other Intangible Assets Governing Law
Governmental Authority Governmental Proceedings
Gross Margin Guarantee Joinder Agreement
Guaranteed Obligations Guarantor
Guarantor Joinder Agreement Guidance
Hardship Distributions Hazardous Material
Hazardous Materials Hedging Agreement
High Risk Funds Invested Research Not Generate Financial Hiv
Hsr Act Impact Benefits
Impact Future Change Control Impact Voluntary Withdrawal Vioxx
Impairments Investments Impairments Long-lived Assets
Implementation Sfas 123r Important Notice Regarding Availability Proxy Materials Annual Meeting
Incentive Stock Plan Incentives
Including Amendments Supplements Because They Contain Important Information Income Statement
Income Taxes Incremental Facility
Incumbent Director Resignation Policy Incurrence Indebtedness
Indebtedness Indebtedness Management
Indemnitee Independence Determinations
Independence Directors Independent Auditors Consent
Independent Lead Director Index
Index Debt Index Exhibits
Individual Agreements Infectious Disease
Information Information Merck Shareholders
Initial Crediting Initial Election Defer
Initial Election Distribution Schedule Insurance
Insurance Coverage Product Liability Limited Cost Prohibitive Unavailable Intangible Assets
Integration Information Answers Integration Process
Integration Work Begin Right Away Intellectual Property Rights
Interest Election Request Interest Payment Date
Interest Period Interest Rate Risk Management
International Lawsuits Introductory
Inventories Inventories Produced Preparation Product Launches
Investigations Investing Activities
Investors Urged Read Registration Statement Joint Proxy Including Issues Concerning Merck Schering-plough Cholesterol Joint Ventures Clinical
Issues Concerning Vytorin Enhance Seas Clinical Trials Material Johnson Johnson°merck Consumer Pharmaceuticals
Johnson Johnsonºmerck Consumer Pharmaceuticals Joint Proxy Statement Including Amendments Supplements Because They
Joint Venture Sales Detail Dollars Joint Venture Service
K-dur Antitrust Litigation Key Divisional Functional Progress
Key Schering-plough Products Generate Significant Amount Schering-ploughs Profits Know-how
Knowledge Knowledge Sanofi-aventis
Law Lead Director
Legal Proceedings Connection Merger Outcomes Uncertain Delay Prevent Legal Proceedings Related Merck Combination
Legal Proceedings Related Merck Transaction Lender
Lenders Letter Credit
Level Valuation Techniques Liabilities
Libo Rate License Arrangements Centocor
Lien Limitation Action
Limitation Compensation Limitations
Liquidity Financial Resources Litigation Investigations Relating Merck Schering-plough Cholesterol Joint Venture
Litigation Matters Loan Documents
Loan Exposure Loans
Long Term Incentive Guidelines Long-lived Assets Geographic Location
Long-term Financial Targets Long-term Incentive Guidelines
Long-term Incentive Plans-awards Last Long-term Incentives
Long-term Investments Loss
Lti Scheduled Grant Date Lti Scheduled Grant Dates
Luding Amendments Supplements Because They Contain Important Information M-m-r
Mac Maintain Focus 2009 Revenue Commitment Longer-term Strategy
Mandatory Convertible Preferred Stock Manner Elections
Manufacturing Sales Marketing Manufacturing Streamlining
Manufacturing Update Market Forces Continue Evolve Impact Schering-ploughs Ability Sell
Marketing Administrative Master Agreement
Material Adverse Change Material Adverse Effect
Material Nonpublic Information Materials Production
Mature Brands Maturity Date
Membership Requirements Merck
Merck Announces 2009 Financial Results Merck Change Control
Merck Common Stock Merck Evp Cfo
Merck Experiencing Difficulties Delays Manufacturing Certain Products Merck Faces Merger Completed Prior Resolution Litigation New
Merck Faces Significant Litigation Related Vioxx Merger Consummated Merck Inc
Merck Inc 2006 Non-employee Director Stock Option Plan Merck Prices 425 Debt Offering
Merck Reports Proposed Settlement Litigation Involving Planned Merger Merck Schering-plough
Merck Schering-plough Cholesterol Partnership Combined Balance Sheets Merck Schering-plough Cholesterol Partnership Combined Statements Cash Flows
Merck Schering-plough Cholesterol Partnership Combined Statements Net Sales Merck Schering-plough Cholesterol Partnership Combined Statements Partners Capital
Merck Schering-plough Combined Incur Significant Transaction Merger-related Transition Merck Schering-plough Dependent Patent Rights Invalidated Circumvented Business
Merck Schering-plough Involved Arrangements Parties Restrict Mercks Schering-ploughs Merck Schering-plough Partnership
Merck Schering-plough Subject Business Uncertainties Contractual Restrictions While Merck Schering-plough Subsequently Combined Continue Retain Motivate Recruit
Merck Schering-plough Subsequently Combined Subject Changes Tax Laws Merck Supplemental Indenture
Mercks Business Environment Mercks Inability Obtain Financing Necessary Complete Transaction Delay
Merger Merger Agreement
Merger Control Authority Merger Restructuring Program
Merger Update Merial Balance Sheet
Merial Business Products Merial Closing Accounts
Merial Contribution Value Merial Enterprise Value
Merial Equity Interests Merial Group
Merial Indemnified Tax Entities Merial Issuance
Merial Limited Merial Mac
Merial Plan Merial Product Registrations
Merial Share Value Merial Shares
Merial Value Miscellaneous
Mixed-use Intellectual Property Modifications Distribution Schedule
Moody8217s Moody8217s Rating
Mportant Information Multi-jurisdictional Regulations Including Those Establishing Schering-ploughs Ability Price
Multiemployer Plan Multiplies
Mutual Funds Name Person Filing Proxy Statement Other Registrant
Ncluding Amendments Supplements Because They Contain Important Information Negative Events Animal Health Industry Impact Future Results
Net Balance Sheet Liabilities Net Cash Proceeds
Net Debt Net Income Earnings Per Common Share
Net Income Earnings Per Share Net Sales Customer
Net Sales Geographic Area Net Sales Segment
Neuroscience Ophthalmology New Confidentiality Agreement
New Credit Facilities New Merck Face Intense Competition Lower-cost Generic Products
New Merck Face Intense Competition Products New Merck Parties Acting Mercks Behalf Subject Governmental
New Mercks Research Development Efforts Not Succeed Developing New Plan Benefits
New Products Technological Advances Developed Schering-ploughs Competitors Negatively Non-i Business
Non-us Nonqualified Deferred Compensation
Nontransferability Not
Notes Pro Forma Condensed Combined Financial Statements Now Therefore
Number 7954610000 Objectives
Objectives Policies Objects Purposes
Oecd Offset Suspension Exercise
Old Merck Commercial Paper Guarantee Old Merck Credit Agreements Guarantees
Oncology Operating Activities
Options Order
Ordinary Course Ordinary Course Business
Ors Urged Read Registration Statement Joint Proxy Including Osteoporosis
Other Assets Other Commitments
Other Discussion Cash Flows Other Events
Other Expense Income Net Other Fees
Other Income Expense Net Other Income Expense Net Dollars
Other Information Other Lawsuits
Other Legal Matters Adverse Outcomes Negatively Affect New Other Legal Matters Adverse Outcomes Negatively Affect Schering-ploughs
Other Litigation Other Matters
Other Named Executive Officers Other Named Executive Officers-objectives Performance
Other Product Liability Litigation Other Provisions
Other Share-based Awards Other Taxes
Overview Overview Schering-plough
Parent Part
Part Financial Information Participant
Parties Party
Patent Challenges Hatch-waxman Act Patent Disputes Costly Prosecute Defend Adverse Judgments Result
Patent Litigation Patent Matters
Patents Payments Due Period
Pbgc Pending Administrative Obligations
Pensions Other Postretirement Benefit Plans Percent Vote Requirement Amendments Certain Provisions Restated Certificate
Percent Vote Requirement Amendments Stockholders Provisions By-laws Governing Percent Vote Requirement Certain Business Combinations Greater-than-5 Stockholder
Percent Vote Requirement Removal Directors Cause Stockholders Performance Awards
Performance Graph Performance Share Awards
Performance Share Units Performance-based Deferred Stock Units
Period Permitted Commercial Paper
Permitted Encumbrance Permitted Encumbrances
Permitted Existing Indebtedness Permitted Indebtedness
Permitted Refinancing Permitted Repurchase Indebtedness
Perquisites Person
Peter Kim Pharmaceutical
Pharmaceutical Products Develop Unexpected Safety Efficacy Concerns Pharmaceutical Segment Revenues
Pipeline Update Plan
Plan Amendment Termination Plan Assets Fair Value
Plan Deferred Payment Directors Compensation Plan Descriptions
Policy Deductibility Compensation Political Purposes
Post-merger Stub Period Post-spa Closing Tax Period
Potential Payments Termination Change Control Pplements Because They Contain Important Information
Pre-approval Policy Services Independent Registered Public Accounting Firm Pre-existing Condition
Pre-merger Stub Period Preferred Shares
Preferred Stock Preliminary Allocation Consideration Transferred Net Assets Acquired
Pricing Pressures Primarily Related Business
Primary Obligor Prime Rate
Principles Combination Principles Consolidation
Pro Forma Condensed Combined Statement Income Proceeds
Product Liability Insurance Products Limited Cost Prohibitive Unavailable Product Performance Animal Health
Product Performance Consumer Health Product Performance Highlights
Product Performance Human Health Product Registrations
Products Canadian Wholesalers Products Liability
Profit Loss Segment Program
Progress Begins Step Property
Property Loss Event Proposal Adopt 2006 Non-employee Directors Stock Option Plan
Proposal Adopt 2007 Incentive Stock Plan Proposal Amend Restated Certificate Incorporation Eliminate Supermajority Voting
Proposal Amend Restated Certificate Incorporation Limit Size Board Provided
Provision Income Taxes Proxy Solicited Behalf Board Directors
Psus Psychiatric Disease
Public Authority Purchase Money Indebtedness
Purchases Stock Corporation Purpose
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Highlights
Question Answer Questions Answers Annual Meeting Voting
Quorum Ratification Appointment Independent Registered Public Accounting Firm
Rating Rating Level Change
Rating Level Period Raymond Gilmartin
Readiness Recent Financial Crisis Current Uncertainty Global Economic Conditions
Recently Issued Accounting Standards Redesignations
Reduction Exercise Price Register
Registered Office Agent Registration Statement Joint Proxy Including Amendments Supplements Because
Regulation Regulatory Competitive Environment
Regulatory Compliance Post-marketing Surveillance Regulatory Inspections
Regulatory Reform Related Business
Related Merial Business Related Parties
Related Person Transaction Policy Related Person Transactions
Related Schering-plough Non-i Business Relationships Outside Firms
Reliance Party Relationships Outsourcing Arrangements Adversely Affect Consequently Report Executive Compensation
Report Independent Registered Public Accounting Firm Reportable Event
Representatives Repurchase Agreement
Required Lenders Requirement Law
Research Development Research Development Update
Research Future Products License Agreement Reserves
Restricted Investment Restricted Investments
Restricted Payment Restricted Stock Grants
Restricted Stock Grants Performance Share Awards Restricted Stock Units
Restricted Stock Units Performance Share Restrictive Agreement
Restructuring Costs Result Merger New Merck Significant Global Operations Expose
Results Highlights 2009 Results Operations Financial Condition
Retirement Benefit Assumptions Retirement Plan Benefits
Return Return Incentive Compensation Executive
Revenue Recognition Revenue Recognition Rebates Returns Allowances
Richard Clark Right Employment
Right Employment Participation Risk Factors
Risks Policy Objectives Risks Related New Merck After Completion Merger
Rofr Period Rsus
Rtant Information S-p Supplemental Indenture
Sale Lease-back Transaction Sanofi Pasteur Msd
Sanofi-aventis Plan Satisfaction Date
Schedule Schedule 1212
Schedule 128 Schedule 14a
Schedule Director Fees Schering-plough
Schering-plough Corporation Schering-plough Exposed Market Risk Fluctuations Currency Exchange Rates
Schering-plough Relies Third-party Relationships Key Products Conduct Changing Schering-plough Subject Evolving Complex Tax Laws Result Additional
Schering-ploughs Global Operations Expose Schering-plough Additional Risks Adverse Schering-ploughs Mercks Merger Completed New Products Including Development
Schering-ploughs Success Dependent Successful Development Marketing New Products Scientific Research
Scorecard Securities Class Action Litigation
Securities Rating Not Recommendation Buy Sell Hold Subject Securitization
Securitization Facility Securitization Spv
Segment Profits Segment Revenues
Select Business Highlights Selected Data
Sellers Sellers Animal Health Executive
Sellers Plan Selling General Administrative
Senior Notes Senior Unsecured Notes
Separation Separation Benefits
Separation Change Control Arrangements Separation Change Control Other Arrangements
Separation Plan Payment Benefit Estimates Separation Service
Share Purchase Agreement Share Purchase Straddle Period
Share Units Share-based Compensation
Shared-service Employees Shareholder Lawsuits
Shareholder Proposal Shares
Shares Available Incentives Shares Subject Plan Adjustments
Shipping Handling Expenses Short-term Investments
Signatures Significant Subsidiary
Signing Date Spa Closing
Spa Closing Date Spa Closing Date Balance Sheet
Special Acquisition-related Charges Special Bonus Awards
Special Charges Special Provisions Options
Special Provisions Performance Special Rules Redesignation Out Merck Common Stock
Special Shareholder Meetings Special Shareowner Meetings
Specified Asset Sale Specified Employee
Specified Equity Issuance Specified Incurrence Indebtedness
Specified Issuer Specified Taxes
Spin-off Distribution Merck Shareholders Equity Securities Medco Health State Other Jurisdiction Incorporation
Statement Joint Proxy Including Amendments Supplements Because They Statement Kenneth Steiner
Statement Support Statement William Steiner
Statutory Reserve Rate Stock Appreciation Rights
Stock Option Plan Stock Options
Stock Ownership Guidelines Stock Units
Stockholder Action Stockholder Communications Board
Stockholder Proposal Concerning Advisory Vote Executive Compensation Stockholder Proposal Concerning Animal Welfare Policy Report
Stockholder Proposal Concerning Independent Lead Director Stockholder Proposal Concerning Management Compensation
Stockholder Proposal Concerning Non-director Shareholder Votes Stockholder Proposal Concerning Publication Political Contributions
Stockholder Proposal Concerning Special Shareholder Meetings Stockholder Proposal Concerning Stock Option Awards
Stockholder Proposal Concerning Subjecting Non-deductible Executive Compensation Shareholder Straddle Period
Strategic Alliances Strategy
Strategy Focused Science Subsidiaries
Subsidiary Subsidiary Guarantor
Subtracts Successors Employer
Summary Actions Regarding Annual Ceo Compensation Decisions Supplemental Sales Information
Supplements Because They Contain Important Information Supporting Statement
Surviving Facilities Surviving Revolving Facilities
Svp Global Compliance Business Practices Schering-plough Svp Global Quality Operations Schering-plough
Systems Comet Launch Table Contents
Tatement Including Amendments Supplements Because They Contain Important Tatement Joint Proxy Statement Including Amendments Supplements Because
Tax Tax Fees
Tax Matter Tax Matters
Taxes Taxes Income
Taxing Authority Teams Also Work Closely Members Schering-plough Integration Face-to-face
Term Loan Term Plan
Termination Termination Agreement
Termination Employment Therefore
Third-party Payor Actions Through Innovations Patients
Ticket Admits Named Stockholder Guest Timing Election
Tion Statement Joint Proxy Including Amendments Supplements Because Top Form
Total Compensation Total Debt
Total Debt Capitalization Ratio Total Sales Volume Price Exchange
Trademarks Transaction Subject Receipt Certain Required Clearances Approvals Governmental
Transactions Transactions Related Persons
Transfer Tax Transferability
Tredaptive Cordaptive Update Type
Ubs Analyst Until
Upplements Because They Contain Important Information Urged Read Registration Statement Joint Proxy Including Amendments
Vaccine Litigation Vaccines
Vaccines Segment Revenues Valuation Date
Valuation Deferred Compensation Accounts Value
Vioxx Litigation Update Voting Stock
Vytorin Zetia Whereas
Withholding Taxes Witness Whereof
Womens Health Endocrine Year-end 2006
Yes-vote Zolinza
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki